NuVasive, a medical device company focused on transforming spine surgery, expanded its revolving line of credit from $150 million to $500 million.

“NuVasive is off to a solid start to the year, with our International business exceeding our expectations, and we saw momentum building in our U.S. business as we exited the quarter,” said Gregory T. Lucier, chairman and CEO of NuVasive. “We are on track to deliver non–GAAP operating profit margin expansion of at least 100 basis points in 2017, reflecting our continued focus on operational efficiencies and the ramp up of our in-house manufacturing facility. Coupled with several innovative product and systems launches planned for 2017, including LessRay designed for radiation reduction, RELINE Trauma system, expandable cages and UNYTE system for complex fractures, we anticipate strong revenue acceleration for the balance of the year.”

The company expects the expanded facility to allow greater flexibility in planning for the maturity of its convertible notes due July 2017 and to support future investment in organic and inorganic growth initiatives.

According to a related 8-K filing, Bank of America served as administrative agent, swingline lender and L/C issuer. Wells Fargo was syndication agent. MUFG Union Bank and Royal Bank of Canada were co-documentation agents. Merrill Lynch Pierce Fenner and Smith was sole lead arranger and sole bookrunner.